Associations between dietary antioxidant intakes and cardiovascular disease

Parvin Mirmiran1,3, Firoozeh Hosseini-Esfahani1,3*, Zohreh Esfandiar1, Somayeh Hosseinipour-Niazi1 & Fereidoun Azizi2

Cardiovascular disease (CVD), as the leading cause of death worldwide, is the collective term named for disorders afflicting the blood vessels and heart. Inflammation and enhanced oxidative stress have been shown as fundamental risk factors in the onset and progression of CVD. Chronic inflammatory conditions attenuate blood levels of antioxidants because of the continuous generation of elevated levels of reactive oxygen species (ROS). A sufficient intake of antioxidants is also suggested to beneficially interfere with CVD by quenching ROS. Antioxidant vitamins and minerals, such as vitamins A, E, and C, and zinc may slow the development and progression of CVD. This study aimed at investigating the association between daily consumption of dietary vitamins A, E, and C, and zinc and the incidence of CVD. Eligible adults (n = 5102) aged ≥ 30 years, were selected from the participants of the Tehran lipid and glucose study with an average follow-up of 5.3 years. Dietary intake was assessed using a valid and reliable semi-quantitative food frequency questionnaire. Anthropometrics and biochemical variables were evaluated at baseline and follow-up examinations. Multivariable Cox proportional hazard regression models were used to estimate the development of CVD associated with total intakes of vitamins A, E, and C, and zinc. This study was conducted on 2253 men and 2849 women aged 47.0 ± 11.6 and 45.6 ± 10.5 years, respectively. The main sources of dietary vitamins A, E, and C and zinc were fruits, vegetables, and legumes. Risk of CVD decreased from quartile 1 to quartile 4 for vitamin E intake (HR 1.00, 0.91, 0.77, and 0.57; \( P_{\text{trend}} = 0.03 \)). The association between the risk of CVD and quartiles of vitamins A, and C and zinc intake was not statistically significant. Our study suggests an inverse association between vitamin E intake and the risk of CVD, emphasizing the potential protective role of fruit and vegetable in the prevention of CVD.

Cardiovascular disease (CVD), as the leading cause of death worldwide, is the collective term named for disorders afflicting the blood vessels and heart that accounts for 17.9 million deaths in 20161. Inflammation and enhanced oxidative stress have been shown as fundamental risk factors for the onset and progression of CVD. Chronic inflammatory conditions attenuate blood levels of antioxidants because of the continuous generation of elevated levels of reactive oxygen species (ROS). Sufficient intake of antioxidants is also suggested to beneficially interfere with CVD by quenching ROS3.

Antioxidant vitamins and minerals, such as vitamins A, E, and C, and zinc may slow the development and progression of CVD4,5. Observational epidemiological studies have suggested that a higher circulating concentration of vitamin E was associated with a lower risk of CVD6. Therefore, these findings indicate the need for additional and more accurate clinical investigations in this area.

Vitamin C is a major water-soluble antioxidant in plasma, and observational studies have shown an inverse association between dietary vitamin C and CVD outcomes7,8. However, in several large randomized controlled trials, the effect of vitamin C to prevent CVD has not been confirmed. Although the antioxidant potential of vitamin A was first determined in 19329, limited data are available regarding the association between vitamin A and the risk of CVD10. Zinc is an essential trace metal with antioxidant and anti-inflammatory activities; insufficient intake of zinc has persistently been reported in CVD patients11. Trace element analysis of hair showed that patients with CVD had lower levels of zinc12. A 6-year follow-up cohort study on CVDs and dietary zinc.
intake reported no association between CVD and total zinc intake; therefore, further investigations, as well as additional evidence obtained by observational studies are required.

Accordingly, studies on the association between CVD and the antioxidant vitamins and minerals such as vitamins A, E, and C and zinc cannot shape the dietary guidelines regarding the nutritional value of these factors; therefore, the need to investigate the risk of CVD by dietary antioxidant vitamin and mineral intakes is warranted. Also, as far as we know, there is limited evidence about the association between antioxidant vitamins or minerals and the risk of CVD in Asian populations. Hence, we aimed to prospectively evaluate the association between dietary antioxidant intakes (vitamins A, E, and C and zinc) and the risk of CVD in a group of adults in Tehran, Iran.

Methods

Study population. In this cohort study, the subjects were selected from participants of the Tehran lipid and glucose study (TLGS), a population-based prospective study to determine the risk factors for non-communicable diseases among the residents of District 13, Tehran, the capital city of Iran. The first examination survey was performed from 1999 to 2001 on 15,005 individuals aged ≥ 3 years, using the multistage stratified cluster random sampling, and follow-up examinations were conducted every 3 years; 2002–2005 (survey 2), 2005–2008 (survey 3), 2008–2011 (survey 4), and 2012–2015 (survey 5) to identify recently developed diseases.

Of 14,712 individuals participating at baseline (surveys 3 and 4), 9057 subjects were randomly selected for dietary assessment based on age- and sex-stratified random sampling, of whom 5531 subjects aged ≥ 30 years at baseline with completed data were included and followed until 2014. Subjects (n = 227) with under- or over-reporting of energy intake (< 800 or ≥ 4200 kcal/day) and also those with a history of CVD (n = 414) at baseline were excluded. Finally, after excluding participants with missing any follow-up data (n = 15), 5102 subjects remained and entered in the analysis (Fig. 1).

All participants signed a written informed consent form before the research. The study was conducted based on the Declaration of Helsinki and the study protocol was accepted by the Ethics Committee of the Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. All methods were performed in line with the relevant guidelines and regulations. Materials and methods were checked using the strengthening of the reporting of observational studies in epidemiology (STROBE) statement.

Dietary intake measurements. Dietary assessment was performed by a valid and reliable 168-item semi-quantitative food frequency questionnaire (FFQ). Trained interviewers collected information on usual dietary intake through face-to-face private interviews. The frequency of eating each food item on a daily, weekly, or monthly basis was recorded and daily intakes was computed via the consumption frequency multiplied by the portion size of each food item, and then the portion sizes were converted into grams using household measures. The weight of seasonal foods, like some fruits, was calculated based on the number of seasons when each food was accessible. The Iranian food composition table (FCT) is incomplete; thus the amounts of energy and nutrient contents were estimated according to the United States Department of Agriculture (USDA) FCT; however, the Iranian FCT was used for some national products (like Kashk) that are not listed in the USDA FCT. Dietary intakes of vitamins E, C, and A and zinc were calculated and considered in grams per week. Vitamin A consumption was considered as taking retinol and its esterified form.

Physical activity. Physical activity level was assessed using the Persian translation of the modifiable activity questionnaire (MAQ) with high reliability and moderate validity. The time and frequency of the light, moder-
ate, high, and very high intensity activity were obtained according to the list of common activities of daily living over the past year and results were transformed into metabolic equivalent- hours/week (Met/h/week)²³.

**Blood pressure and anthropometric measurements.** Systolic and diastolic blood pressures (SBP and DBP) were measured twice (with a 30 s interval) in a sitting position after 15 min of rest¹⁵,¹⁶.

The body weight was measured to the nearest 100 g, using a digital scale (Seca 707) while the subjects were minimally clothed and without shoes. Height was measured to the nearest 0.5 cm by a tape measure in a standing position without shoes and with shoulders in normal alignment. Waist circumference (WC) was measured with a non-flexible tape meter without any pressure to the body surface at the level of the umbilicus²⁴ and was taken at the end of a normal expiration over light clothing. Measurements were recorded to the nearest 0.1 cm.

**Laboratory assays.** Blood samples were drawn into vacutainer tubes between 7:00 and 9:00 a.m., after a 12–14-h overnight fast in a sitting position and centrifuged within 30 to 45 min of the collection. All biochemical analyses were performed using a Selectra 2 auto-analyzer at the TLGS research laboratory on the blood collection day. Fasting blood glucose (FBG) concentration was measured on the blood collection day using the colorimetric glucose oxidase procedure. The standard 2-h post-challenge blood glucose test was performed by oral administration of 82.5 g of glucose monohydrate solution (or 75 g of anhydrous glucose) for those who did not take glucose-lowering drugs¹⁵,¹⁶.

High-density lipoprotein cholesterol (HDL-C) concentration was assessed after precipitation of the apolipoprotein B-containing lipoproteins by phosphotungstic acid. Total cholesterol (TC) and triglyceride (TG) were measured using the enzymatic colorimetric method. For TC assay, cholesteryl ester hydrolysis was used to convert cholesteryl ester to cholesterol, which was then oxidized by cholesterol oxidase to cholesterol-4-en-3-one and H2O2. TG was broken down to glycerol and free fatty acids using lipoprotein lipase and glycerol was then phosphorylated to glycerol phosphate by glycerol kinase. Glycerol phosphate was then converted to dihydroxyacetone phosphate and H2O2 by glycerol phosphate oxidase. The Friedewald equation (LDL-C = TC – HDL-C – TG/5) was used to calculate LDL-C concentration in samples containing TG²⁵.

**Definitions.** Details of the collection of CVD outcome data have been described elsewhere. Coronary heart disease (CHD) events included definite myocardial infarction (diagnostic electrocardiographic [ECG] results and biomarkers), probable myocardial infarction (positive ECG findings plus cardiac symptoms or signs plus missing biomarkers or positive ECG findings plus equivocal biomarkers), proven CHD by angiography, unstable angina pectoris (new cardiac symptoms or changing symptom patterns and positive ECG findings with normal biomarkers), and CHD mortality. CVD was defined as stroke (a new neurological deficit that lasted more than 24 h), CHD events, or CVD death (a fatal stroke or fatal CHD)²⁶.

Sex-specific multivariable risk functions (“general CVD” algorithms) were derived that incorporated the age, TC, HDL-C, SBP, treatment for hypertension, smoking, and type 2 diabetes status²⁷. Hypertension was defined as SBP ≥ 140, DBP ≥ 90 mmHg, or receiving antihypertensive drug²⁸.

**Statistical analyses.** Statistical analyses were carried out using the Statistical Package for Social Sciences (version 21.0; SPSS). A two-tailed P value < 0.05 was used to determine statistical significance. We used a Chi-square test and Student’s t-test for qualitative and quantitative variables to compare the results obtained from the male and female subjects. For non-normal nutritional and biochemical variables (TG concentration), log-transformed values were used for statistical analysis. Antioxidant intakes with respect to quartiles of food group intakes were assessed using ANOVA test. P for trend was obtained by the linear regression analysis using the median of each quartile as a continuous variable for each food group.

The hazard ratio (HR) and 95% confidence interval (CI) of CVD incidence were assessed using multivariable Cox proportional hazard regression models. Person-years of the follow-up were calculated for each individual from the date inclusion in the study and the exact date of CVD diagnosis, death, or end of the follow-up, whichever came first. Survival time for censored individuals was calculated as the interval between the first and the last observation dates.

The event date was considered as the exact date of CVD events, and survival time was computed as the time between baseline examination and the event date (for event cases) or the last follow-up (for censored cases). Participants were censored due to loss to follow-up, death from a cause other than CVD, or the end of the study without the event appearing.

Rates of CVD-free survival in participants across quartiles of vitamins E, C, and A and zinc intakes were compared using a Kaplan–Meier analysis and the log-rank test method was used for significance test.

The incidence of CVD during the follow-up period was considered as dichotomous variables (yes/no) in the models. The dietary intakes of vitamins E, C, and A, and zinc were adjusted for energy intake using gram per 1000 kcal for each nutrient. Energy adjusted of vitamins E, C, and A, and zinc intakes were categorized into quartiles, given the first quartile as the reference. The median of each quartile was used as a continuous variable to assess the overall trends of HRs across quartiles of dietary intakes of vitamins E, C, and A and zinc in the Cox proportional hazard regression models. Trend test was applied for evaluating dose–response effects in association studies. The proportional hazard assumption of the multivariable Cox models was assessed using Schoenfeld’s global test of residuals.

The confounders were selected based on previous studies and included in the univariable Cox regression model. A two-tailed P value < 0.20 was used for inclusion in the model²⁹. The Cox regression models were adjusted for age, sex, CVD risk score (continuous), family history of CVD, physical activity (continuous), dietary intakes of total energy, energy-adjusted fiber (g/1000 kcal) and total fat (percentage of energy).
Results
The mean age of subjects at baseline was 47.0 ± 11.6 and 45.6 ± 10.5 years in men and women, respectively. Table 1 represents the baseline characteristics of men and women. Men were older, had worse smoking habits, greater levels of physical activity, lower body mass index, and higher WC than women. In addition, men had higher values of SBP, DBP, total cholesterol, TG/HDL-ratio, and FBG except for 2 h- plasma glucose. Men had greater amounts of energy and carbohydrate intakes than women. Intakes of total fat, saturated fatty acid, monounsaturated fatty acid, polyunsaturated fatty acid, fiber, and vitamins A and C were higher in women than in men.

The association between dietary intakes of vitamins E, C, and A and zinc across quartiles of food groups are presented in Table 2. Higher consumption of fruit, vegetable, legumes, refined grains, vegetable oils, fish, and poultry was associated with higher intake of vitamin E. Vitamin C intake was positively associated with all food groups, except for refined grains and red meat that showed a negative association with vitamin C intake. There was a positive association between vitamin A and quartiles of all food groups, except for red meat. Compared with those in the lower quartiles, zinc intake was significantly higher among individuals in the upper quartiles of fruit, vegetable, legumes, whole grains, refined grains, dairy, fish, and poultry intake.

Kaplan–Meier survival curves for CVD according to quartiles of vitamins A, C, and E and zinc intakes during follow-up periods are shown in Figs. 2, 3, 4 and 5. Significant differences were found in the risk of CVD between quartiles of zinc intake.

HRs (95% CI) of CVD for quartiles of dietary antioxidants (vitamins A, E, and C, and zinc) intakes are presented in Table 3. After adjustment for potential confounders, the risk of CVD decreased from quartile 1 to quartile 4 for vitamin E intake [HR 1.00, 0.91 (0.62–1.64), 0.77 (0.51–1.18), and 0.57 (0.34–0.97); Ptrend = 0.03]. The association between the risk of CVD and quartiles of vitamins A and C, and zinc intake were not statistically significant.

Discussion
The current investigation was a prospective cohort study, evaluating the association between dietary antioxidant (vitamins A, E, and C and zinc) intakes and risk of CVD. Our results suggested that a higher intake of vitamin E was inversely associated with CVD incidence.

Table 1. Baseline characteristics of adult participants of the Tehran Lipid and Glucose Study. MET, metabolic equivalent; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MUFA, mono-unsaturated fatty acids; PUFA, poly-unsaturated fatty acids; SFA, saturated fat. *Values are mean ± SD unless otherwise listed. P values derived through Student's t-test and chi-square test for quantitative and qualitative variables, respectively.
| Food groups       | Vitamin E (mg) | Vitamin C (mg) | Vitamin A (µg) | Zinc (mg) |
|-------------------|----------------|----------------|----------------|-----------|
| **Fruits**        |                |                |                |           |
| Q1: 0.70 ± 0.27   | 9.7 ± 4.7      | 79.7 ± 44.1    | 421 ± 256      | 11.3 ± 8.1 |
| Q2: 1.60 ± 0.27   | 10.8 ± 10.8    | 123 ± 36.4     | 534 ± 320      | 12.9 ± 10.3 |
| Q3: 2.69 ± 0.38   | 14.0 ± 66.2    | 178 ± 89.0     | 625 ± 351      | 15.3 ± 66.5 |
| Q4: 5.59 ± 2.55   | 14.1 ± 5.0     | 300 ± 137      | 822 ± 446      | 15.1 ± 14.3 |
| P for trend       | <0.001         | <0.001         | <0.001         | 0.01      |
| **Vegetables**    |                |                |                |           |
| Q1: 1.89 ± 0.53   | 9.1 ± 4.5      | 101 ± 83.4     | 357 ± 212      | 10.5 ± 8.7 |
| Q2: 3.28 ± 0.36   | 11.0 ± 4.5     | 145 ± 94.4     | 492 ± 213      | 12.2 ± 7.9 |
| Q3: 4.57 ± 0.39   | 12.3 ± 5.3     | 183 ± 92.5     | 632 ± 278      | 13.4 ± 10.3 |
| Q4: 7.66 ± 2.82   | 16.1 ± 66.2    | 251 ± 142      | 920 ± 484      | 18.5 ± 67.3 |
| P for trend       | <0.001         | <0.001         | <0.001         | <0.001    |
| **Legumes**       |                |                |                |           |
| Q1: 0.02 ± 0.01   | 11.6 ± 5.3     | 157 ± 126      | 514 ± 341      | 11.6 ± 6.7 |
| Q2: 0.07 ± 0.01   | 11.8 ± 5.6     | 172 ± 122      | 598 ± 389      | 13.0 ± 10.6 |
| Q3: 0.15 ± 0.02   | 11.5 ± 4.8     | 167 ± 107      | 613 ± 360      | 13.7 ± 12.6 |
| Q4: 0.35 ± 0.18   | 13.6 ± 8.2     | 183 ± 132      | 677 ± 407      | 18.4 ± 67.0 |
| P for trend       | <0.001         | <0.001         | <0.001         | <0.001    |
| **Whole grains**  |                |                |                |           |
| Q1: 0.10 ± 0.07   | 11.2 ± 5.2     | 149 ± 118      | 511 ± 344      | 11.3 ± 8.3 |
| Q2: 0.44 ± 0.13   | 11.6 ± 5.5     | 167 ± 107      | 599 ± 386      | 12.5 ± 8.7 |
| Q3: 1.31 ± 0.43   | 13.5 ± 66.2    | 175 ± 131      | 622 ± 385      | 14.1 ± 13.7 |
| Q4: 5.01 ± 3.79   | 12.5 ± 4.8     | 189 ± 123      | 669 ± 384      | 16.7 ± 66.9 |
| P for trend       | 0.25           | <0.001         | <0.001         | 0.002     |
| **Refined grains**|                |                |                |           |
| Q1: 4.90 ± 1.34   | 10.6 ± 5.7     | 173 ± 126      | 614 ± 432      | 11.0 ± 8.1 |
| Q2: 7.12 ± 0.72   | 11.3 ± 5.1     | 168 ± 111      | 591 ± 347      | 12.3 ± 10.9 |
| Q3: 10.0 ± 0.95   | 12.0 ± 5.0     | 173 ± 118      | 607 ± 378      | 14.0 ± 12.8 |
| Q4: 16.6 ± 5.29   | 14.6 ± 66.2    | 166 ± 129      | 590 ± 356      | 17.4 ± 66.7 |
| P for trend       | 0.02           | 0.007          | 0.004          | <0.001    |
| **Dairy products**|                |                |                |           |
| Q1: 0.92 ± 0.30   | 12.3 ± 66.3    | 137 ± 119      | 449 ± 325      | 12.5 ± 67.4 |
| Q2: 1.69 ± 0.18   | 11.2 ± 4.6     | 161 ± 108      | 644 ± 332      | 12.2 ± 7.8 |
| Q3: 2.35 ± 0.22   | 11.9 ± 5.0     | 181 ± 125      | 624 ± 344      | 13.6 ± 9.4 |
| Q4: 3.71 ± 1.07   | 13.1 ± 5.5     | 201 ± 123      | 785 ± 326      | 16.2 ± 11.0 |
| P for trend       | 0.19           | <0.001         | <0.001         | <0.001    |
| **Red meat**      |                |                |                |           |
| Q1: 0.07 ± 0.03   | 12.0 ± 5.4     | 181 ± 140      | 612 ± 404      | 13.3 ± 9.2 |
| Q2: 0.16 ± 0.02   | 11.7 ± 4.9     | 172 ± 120      | 602 ± 349      | 13.4 ± 12.0 |
| Q3: 0.27 ± 0.04   | 13.4 ± 66.2    | 168 ± 122      | 595 ± 344      | 14.3 ± 66.3 |
| Q4: 0.60 ± 0.32   | 11.5 ± 5.6     | 159 ± 98.6     | 593 ± 416      | 13.8 ± 13.8 |
| P for trend       | 0.70           | <0.001         | <0.001         | 0.32      |
| **Fish and poultry** |            |                |                |           |
| Q1: 0.41 ± 0.15   | 10.7 ± 4.9     | 148 ± 116      | 499 ± 346      | 11.3 ± 8.3 |
| Q2: 0.84 ± 0.13   | 11.2 ± 4.9     | 161 ± 112      | 654 ± 318      | 12.5 ± 8.7 |
| Q3: 1.32 ± 0.16   | 12.1 ± 5.0     | 174 ± 112      | 627 ± 386      | 14.1 ± 13.7 |
| Q4: 2.92 ± 1.87   | 14.6 ± 66.3    | 197 ± 137      | 722 ± 498      | 16.7 ± 66.9 |
| P for trend       | 0.001          | <0.001         | <0.001         | <0.001    |
| **Sugar-sweetened soft drinks (ml/d)** |      |                |                |           |
| Q1: 0.76 ± 0.95   | 13.1 ± 66.1    | 170 ± 131      | 595 ± 382      | 14.2 ± 66.4 |
| Q2: 8.29 ± 2.23   | 11.1 ± 4.6     | 159 ± 117      | 560 ± 376      | 12.7 ± 11.2 |
| Q3: 24.3 ± 7.59   | 11.7 ± 4.8     | 174 ± 122      | 622 ± 380      | 14.1 ± 14.4 |
| Q4: 109 ± 101     | 12.6 ± 5.7     | 176 ± 113      | 626 ± 377      | 13.8 ± 7.6 |
| P for trend       | 0.55           | <0.001         | <0.001         | 0.68      |
| **Vegetable oils** |                |                |                |           |
| Q1: 2.13 ± 1.25   | 8.4 ± 3.5      | 138 ± 98       | 497 ± 311      | 11.7 ± 9.8 |
| Continued         |                |                |                |           |
| Food groups | Vitamin E (mg) | Vitamin C (mg) | Vitamin A (µg) | Zinc (mg) |
|-------------|----------------|----------------|----------------|-----------|
| Q2: 6.27 ± 0.73 | 10.6 ± 3.5 | 163 ± 116 | 563 ± 341 | 13.0 ± 13.2 |
| Q3: 9.26 ± 1.31 | 13.7 ± 65.9 | 184 ± 141 | 641 ± 392 | 15.5 ± 66.5 |
| Q4: 18.62 ± 8.98 | 16.1 ± 6.4 | 196 ± 118 | 703 ± 434 | 14.5 ± 9.3 |
| P for trend | 0.04 | 0.07 | 0.04 | 0.30 |

Nuts

| Q1: 0.02 ± 0.01 | 11.2 ± 5.1 | 145 ± 109 | 537 ± 379 | 12.5 ± 108 |
| Q2: 0.08 ± 0.01 | 13.6 ± 66.2 | 169 ± 135 | 596 ± 364 | 15.0 ± 66.7 |
| Q3: 0.17 ± 0.03 | 11.7 ± 11.7 | 177 ± 113 | 621 ± 373 | 13.4 ± 11.7 |
| Q4: 0.55 ± 0.42 | 12.0 ± 5.6 | 188 ± 188 | 648 ± 393 | 13.8 ± 10.7 |
| P for trend | 0.96 | < 0.001 | < 0.001 | 0.33 |

Tea and coffee (ml/d)

| Q1: 200 ± 88.1 | 12.7 ± 66.4 | 156 ± 123 | 549 ± 359 | 14.5 ± 67.2 |
| Q2: 379 ± 112 | 11.5 ± 4.8 | 169 ± 118 | 612 ± 398 | 13.1 ± 11.2 |
| Q3: 679 ± 101 | 12.0 ± 4.6 | 175 ± 121 | 613 ± 342 | 13.5 ± 11.2 |
| Q4: 1342 ± 741 | 12.5 ± 6.3 | 179 ± 121 | 628 ± 383 | 13.6 ± 7.8 |
| P for trend | 0.50 | < 0.001 | 0.001 | 0.97 |

Table 2. Antioxidant intakes with respect to quartiles of food group consumption. a Values are serving/day, with the exception of sugar-sweetened soft drinks, Tea and coffee. b Data are mean ± SD using ANOVA test. c P for trend were obtained by the linear regression analysis using the median of each quartile as a continuous variable for each food group.

Figure 2. Kaplan–Meier estimates of CVD-free survival according to quartiles of vitamin E intake. P values by log-rank test and number of CVD outcomes recorded in the groups categorized by vitamin E intake.
Figure 3. Kaplan–Meier estimates of CVD-free survival according to quartiles of vitamin C intake. $P$ values by log-rank test and number of CVD outcomes recorded in the groups categorized by vitamin C intake.

Figure 4. Kaplan–Meier estimates of CVD-free survival according to quartiles of vitamin A intake. $P$ values by log-rank test and number of CVD outcomes recorded in the groups categorized by vitamin A intake.
Previous studies have found an association between dietary vitamin E intake and decreased risk of CVD in observational epidemiologic studies. Several biological functions of vitamin E are due to its antioxidant properties to inhibit the oxidation of LDL-C and to scavenge lipid radicals. In contrast, several large randomized controlled trials have failed to corroborate the benefits of vitamin E in CVD prevention, which can be due to several factors, such as the time of intervention, gene polymorphisms, or inherent confounding, and pathophysiological conditions in study populations. In addition, an intervention study suggested that in addition to prescribed medicine, supplemental doses of vitamin E should be given to ameliorate therapeutic strategies. However, vitamin E supplements have not been recommended by the American heart association to prevent CVD due to the lack of approved results; however, it recommends eating foods rich in antioxidant vitamins, especially fruit and vegetable.

In our study, vitamin E was available in several food groups, which may be due to the connection between food groups, such as consuming oil (olive oil and mayonnaise) and vegetable that are mixed in salads or using oil for cooking. Also, no association was found between nut intake and vitamin E, which may be due to the small quantities of nut consumption in our population.

Anti-CVD properties of vitamin C have not yet been fully confirmed. No significant association was found between total vitamin C intake (estimated by summing the vitamin C contribution of food items and supplements) and CVD in a cohort of Spanish university graduates. Means of fiber-adjusted dietary vitamin C intake (mg/day) across tertiles were 184, 266, and 387, respectively. Therefore, it is concluded that the absence of significant results can be due to the low variability in the exposure. However, vitamin C is a single nutrient and may not represent the synergistic effect of the whole dietary pattern. In contrast to our results, observational studies on the relationship between vitamin C and CVD risk have demonstrated an inverse association between vitamin C and CVD outcomes, especially heart failure and hypertension. The contradiction in results can be due to differences in the definition of CVD. Vitamin C increases the nitric oxide bioactivity of the endothelium, which causes a decrease in blood pressure. Moreover, vitamin C reduces monocyte adhesion and inhibits LDL oxidation, which plays an important role in decreasing the risk of atherosclerosis. In addition, vitamin C keeps atheromatous plaques stable by preventing vascular smooth muscle cell apoptosis.

Consistent with our results, in a meta-analysis, neither dietary nor supplemental vitamin A was associated with CVD risk. A large prospective study indicated that among 4117 patients with stable angina pectoris in the upper tertile of serum vitamin A concentration, serum apolipoprotein B (a predictor of CVD) was associated with the CVD risk. However, dietary intake of vitamin A did not correlate with serum concentration, which seems that another mechanism, other than vitamin A intake, regulates the serum vitamin A concentration. Accordingly, in the current study, no association was observed between dietary vitamin A and CVD risk.
In the present study, no significant difference was found between dietary zinc intake and CVD incidence, which is consistent with a systematic review of prospective cohort studies on the association between dietary zinc intake or serum zinc levels and the incidence of CVD\(^4\). In contrast with our result, higher dietary zinc intake (estimated by summing the zinc contribution of food items) was associated with a greater incidence of CVD in a large longitudinal study on Australian women. Therefore, more investigations are needed to investigate the association between zinc intake from meat and other major sources because dietary guidelines recommend reducing red meat intake and encouraging consuming other sources of zinc\(^4\). Also, more studies are needed to investigate the mechanisms of zinc function on the pathogenesis of CVD to provide dietary zinc recommendations for preventing CVD.

The prospective design of the present study was one of its major strengths that facilitated the estimation of disease incidence without concern about reverse causality between nutrients and outcomes. In this research, the subjects’ reports regarding food consumption were used, whereas multiple assessments of urine or circulating biomarkers of vitamins over time could be a more reliable approach and it was one of the limitations of this study. Considering the observational design of the current research, some confounders (e.g. supplement intake and socioeconomic levels) and comorbidities during follow-up were not considered. Dietary assessment was considered at baseline only, and changes in dietary intakes were not recorded during the follow-up. One of the limitations of this study was the use of an FFQ for collecting dietary data due to recall bias; however, expert dietitians interviewed the participants to reduce this bias. Also, the validity of the FFQ was acceptable among this population.

### Table 3. Hazard Ratios (HR) and 95% CIs for cardiovascular diseases according to quartiles of dietary antioxidants intake. *Test for trend based on ordinal variable containing median value for each quartile. \(^a\) Adjusted for age, sex, CVD risk score, family history of CVD, physical activity, total energy intake, fiber and total fat intakes.

| Variables       | Quartiles of intake | Q1         | Q2         | Q3         | Q4         | \(P_{\text{trend}}\) |
|-----------------|---------------------|------------|------------|------------|------------|----------------------|
| Vitamin E intake | Median, mg/d        | 6.8        | 9.5        | 12.4       | 16.8       |                      |
| Cases, n        | 61                  | 56         | 51         | 38         |            |                      |
| Person-years, n | 6711                | 6530       | 6593       | 6423       |            |                      |
| Follow-up, y    | 5.3                 | 5.2        | 5.2        | 5.1        |            |                      |
| Incidence, %    | 9.0                 | 8.5        | 7.7        | 5.9        |            |                      |
| Crude           | 1.00 ref            | 0.94 (0.65–1.35) | 0.85 (0.58–1.23) | 0.65 (0.43–0.98) | 0.03     |
| Model adjusted\(^b\) | 1.00 ref            | 0.91 (0.62–1.64) | 0.77 (0.51–1.18) | 0.57 (0.34–0.97) | 0.03     |
| Vitamin C intake | Median, mg/d        | 64.7       | 114.2      | 173.3      | 291.6      |                      |
| Cases, n        | 55                  | 52         | 63         | 46         |            |                      |
| Person-years, n | 6844                | 6643       | 6515       | 6256       |            |                      |
| Follow-up, y    | 5.5                 | 5.3        | 5.1        | 5.0        |            |                      |
| Incidence, %    | 6.5                 | 7.8        | 9.6        | 7.3        |            |                      |
| Crude           | 1.00 ref            | 1.19 (0.80–1.77) | 1.47 (1.00–2.16) | 1.13 (0.74–1.70) | 0.58     |
| Model adjusted\(^b\) | 1.00 ref            | 1.04 (0.68–1.59) | 1.19 (0.76–1.85) | 0.84 (0.48–1.48) | 0.44     |
| Vitamin A intake | Median, µg/d        | 267        | 428        | 611        | 964        |                      |
| Cases, n        | 53                  | 60         | 41         | 52         |            |                      |
| Person-years, n | 7020                | 6020       | 6472       | 6145       |            |                      |
| Follow-up, y    | 5.7                 | 5.3        | 5.1        | 5.0        |            |                      |
| Incidence, %    | 7.5                 | 9.0        | 6.3        | 8.4        |            |                      |
| Crude           | 1.00 ref            | 1.21 (0.83–1.75) | 0.84 (0.56–1.27) | 1.13 (0.77–1.67) | 0.81     |
| Model adjusted\(^b\) | 1.00 ref            | 1.16 (0.78–1.70) | 0.82 (0.52–1.28) | 1.00 (0.61–1.63) | 0.74     |
| Zinc            | Median intake (mg/d) | 7.6        | 10.5       | 13.2       | 17.8       |                      |
| Cases, n        | 51                  | 61         | 41         | 53         |            |                      |
| Person-years, n | 6959                | 6728       | 6409       | 6161       |            |                      |
| Follow-up, y    | 5.6                 | 5.3        | 5.1        | 5.0        |            |                      |
| Incidence, %    | 7.3                 | 9.0        | 6.3        | 8.6        |            |                      |
| Crude           | 1.00 ref            | 1.24 (0.85–1.80) | 0.88 (0.58–1.33) | 1.16 (0.81–1.76) | 0.62     |
| Model adjusted\(^b\) | 1.00 ref            | 1.20 (0.80–1.81) | 0.81 (0.49–1.35) | 1.09 (0.58–2.05) | 0.97     |
Moreover, some cases lost the follow-up; for example, those with a high risk of CVD were selectively excluded due to their poor mental or physical health. We did not split the analysis by gender due to the low number of cases and power reduction.

**Conclusion**

This study suggested an inverse association between vitamin E intake and the risk of CVD, which emphasized the potentially protective role of its dietary sources in the prevention of CVD events.

Received: 23 January 2021; Accepted: 13 January 2022

**Published online:** 27 January 2022

**References**

1. Jacob, R. A. Vitamin C nutriture and risk of atherosclerotic heart disease. *Nutr. Rev.* **56**, 334–337 (1998).
2. Ceconi, C., Boraso, A., Cargnoni, A. & Ferrari, R. Oxidative stress in cardiovascular disease: Myth or fact? *Arch. Biochem. Biophys.* **420**, 217–221 (2003).
3. Mange, H., Becker, K., Fuchs, D. & Gostner, J. M. Antioxidants, inflammation and cardiovascular disease. *World J. Cardiol.* **6**, 462–477 (2014).
4. Jain, A. K., Mehra, N. K. & Swarnakar, N. K. Role of antioxidants for the treatment of cardiovascular diseases: Challenges and opportunities. *Curr. Pharm. Des.* **21**, 4441–4455 (2015).
5. Griffiths, K. et al. Food antioxidants and their anti-inflammatory properties: A potential role in cardiovascular diseases and cancer prevention. *Diseases* **4**, 28 (2016).
6. Jayedi, A., Rashidy-Pour, A., Parohan, M., Zargar, M. S. & Shab-Bidar, S. Dietary and circulating vitamin C, vitamin E, beta-carotene and the potentially protective role of its dietary sources in the prevention of CVD events.
7. Pfister, R., Sharp, S. J., Luben, R., Wareham, N. J. & Khaw, K. T. Plasma vitamin C predicts incident heart failure in men and women in European Prospective Investigation into Cancer and Nutrition-Norfolk prospective study. *Am. Heart J.* **162**, 246–253 (2011).
8. Buijsse, B., Jacobs, D. R. Jr., Steffen, L. M., Kromhout, D. & Gross, M. D. Plasma ascorbic acid, a priori diet quality score, and incident hypertension: A prospective cohort study. *PLoS ONE* **10**, e0144920 (2015).
9. Monaghan, B. R. & Schmitt, F. O. The effects of carotene and of vitamin A on the oxidation of linoleic acid. *J. Biol. Chem.* **96**, 387–395 (1932).
10. Olsen, T. et al. Cardiovascular disease risk associated with serum apolipoprotein B is modified by serum vitamin A. *Atherosclerosis* **265**, 325–330 (2017).
11. Lourenço, B. H. et al. Nutritional status and adequacy of energy and nutrient intakes among heart failure patients. *Arg. Bras. Cardiol.* **93**, 541–548 (2009).
12. Sun, Q. et al. Does white rice, brown rice, and rice of type 2 diabetes in US men and women. *Arch. Intern. Med.* **170**, 961–969 (2010).
13. de Oliveira Otto, M. C. et al. Dietary intakes of zinc and heme iron from red meat, but not from other sources, are associated with greater risk of metabolic syndrome and cardiovascular disease. *J. Nutr.* **142**, 526–533 (2012).
14. Kubota, Y. et al. Dietary intakes of antioxidant vitamins and mortality from cardiovascular disease: The Japan Collaborative Cohort Study (JACC) study. *Stroke* **42**, 1665–1672 (2011).
15. Azizi, F. et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. *Trials* **10**, 5 (2009).
16. Hosseini-Esfahani, F. et al. Nutrition and cardio-metabolic risk factors: Findings from 20 years of the Tehran lipid and glucose study. *Int. J. Endocrino. Metab.* **16**, e48742 (2018).
17. Sun, Q. et al. White rice, brown rice, and risk of type 2 diabetes in US men and women. *Arch. Intern. Med.* **170**, 961–969 (2010).
18. Mirmiran, P., Esfahani, F. H., Asghari, G., Mirmiran, P. R. & Azizi, F. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the Tehran Lipid and Glucose Study. *J Epidemiol* **20**, 150–158 (2010).
19. Azar, M. & Sarkisian, E. *Food Composition Table of Iran* (National Nutrition and Food Research Institute, Shahid Beheshti University Press, 1980).
20. United States Department of Agriculture. *Food Composition Table*. USDA. [7 Jan 2015.]. Available from: http://www.nal.usda.gov/fnic/foodcomp.
21. Momenan, A. A., Delshad, M., Sarbazi, N., Rezaei, G. N., Ghanbarian, A. et al. Reliability and validity of the Modifiable Activity Questionnaire (MAQ) in an Iranian urban adult population. *Arch. Iran. Med.* **15**(5), 279–82 (2012).
22. Ainsworth, B. E. et al. Compendium of physical activities: An update of activity codes and MET intensities. *Med. Sci. Sports Exerc.* **32**, 5498–504 (2000).
23. Klein, S. et al. Waist circumference and cardiometabolic risk: A consensus statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. *Am. J. Clin. Nutr.* **85**, 1197–1202 (2007).
24. Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin. Chem.* **18**, 499–502 (1972).
25. Hadad, H., Karimi, M. R. & Azizi, F. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. *Eur. J. Cardiovasc. Prev. Rehabil.* **20**, 571–577 (2006).
26. D’Agostino, R. B. Sr. et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. *Circulation* **117**, 743–753 (2008).
27. Williams, B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *G Ital. Cardiol.* (Rome) **19**, S3–73 (2018).
28. Lee, P. H. & Burstyn, I. Identification of confounder in epidemiologic data contaminated by measurement error in covariates. *BMC Med. Res. Methodol.* **16**, S4 (2016).
29. Rimml, E. B. et al. Vitamin E consumption and the risk of coronary heart disease in men. *N. Engl. J. Med.* **328**, 1450–1456 (1993).
30. Stampfer, M. J. et al. Vitamin E consumption and the risk of coronary disease in women. *N. Engl. J. Med.* **328**, 1444–1449 (1993).
31. Buring, J. E. & Hennekens, C. H. Antioxidant vitamins and cardiovascular disease. *Nutr Rev* **55**, S53–S58 (1997) ([discussion S8–60](https://doi.org/10.1111/j.1753-4887.1997.tb01743.x)).
32. Mathur, P., Ding, Z., Saldeen, T. & Mehta, J. L. Tocopherols in the prevention and treatment of atherosclerosis and related cardio-metabolic disease. *Clin. Cardiol.* **28**, 570–576 (2015).
34. Vardi, M., Levy, N. S. & Levy, A. P. Vitamin E in the prevention of cardiovascular disease: The importance of proper patient selection. *J. Lipid Res.* **54**, 2307–2314 (2013).
35. Sozen, E., Demirel, T. & Ozer, N. K. Vitamin E: Regulatory role in the cardiovascular system. *IUBMB Life* **71**, 507–515 (2019).
36. 2019. American heart association. Vitamin Supplements: Hype or Help for Healthy Eating.
37. Martin-Calvo, N. & Martinez-Gonzalez, M. A. Vitamin C Intake is Inversely Associated with Cardiovascular Mortality in a Cohort of Spanish Graduates: The SUN Project. *Nutrients* **9**, 954 (2017).
38. d’Uscio, L. V., Milstien, S., Richardson, D., Smith, L. & Katusic, Z. S. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. *Circ. Res.* **92**, 88–95 (2003).
39. Salvayre, R., Negre-Salvayre, A. & Camare, C. Oxidative theory of atherosclerosis and antioxidants. *Biochimie* **125**, 281–296 (2016).
40. Slow, R. C., Richards, J. P., Pedley, K. C., Leake, D. S. & Mann, G. E. Vitamin C protects human vascular smooth muscle cells against apoptosis induced by moderately oxidized LDL containing high levels of lipid hydroperoxides. *Arterioscler Thromb. Vasc. Biol.* **19**, 2387–2394 (1999).
41. Myung, S. K. et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: Systematic review and meta-analysis of randomised controlled trials. *BMJ* **346**, f10 (2013).
42. Olson, J. A. Serum levels of vitamin A and carotenoids as reflectors of nutritional status. *J. Natl. Cancer Inst.* **73**, 1439–1444 (1984).
43. Chu, A., Foster, M. & Samman, S. Zinc status and risk of cardiovascular diseases and type 2 diabetes mellitus-a systematic review of prospective cohort studies. *Nutrients* **8**, 707 (2016).
44. Milton, A. H. et al. Prospective study of dietary zinc intake and risk of cardiovascular disease in women. *Nutrients* **10**, 38 (2018).

**Acknowledgements**
The authors are thankful to Kowsar publication for editing the manuscript.

**Author contributions**
Conceptualization, P.M., Z.E. and S.H.N.; Formal analysis, Z.E., F.H.E. and S.H.N.; Methodology, P.M. and F.H.E.; Supervision, F.A.; Writing the original draft, P.M. and Z.E.; Writing review & editing, Z.E. and F.H.E.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to F.H.-E.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2022